New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
12:38 EDTRENN, FSLR, HZNP, ORCL, OWW, FDXOn The Fly: Midday Wrap
Stocks on Wall Street were virtually unchanged at midday as investors await the latest rate decision and associated policy updates from the Federal Reserve. The market spent the morning consolidating its recent gains and stocks moved in a very narrow range since the open. Rates are expected to remain the same and Treasury purchases are expected to be reduced again. Investors and analysts will be paying close attention to the accompanying statement and press conference for clues as to any change in monetary policy. ECONOMIC EVENTS: In the U.S., the fourth quarter current account deficit narrowed to $81.1B, which lower than expected and down from a revised Q3 deficit of $96.4B. Investors await the FOMC meeting announcement, due at 2:00 pm ET, to be followed by Fed Chairwoman Janet Yellen’s press conference at 2:30 pm ET. COMPANY NEWS: Delivery giant FedEx (FDX) reported lower than expected third quarter revenue and earnings per share and lowered its FY14 outlook. Shares were down in pre-market trading but have bounced back to be up just slightly near midday as investors appear to be attributing the earnings miss to the severe winter weather, as the company explained... Another giant corporation, Oracle (ORCL), reported headline earnings and revenue for its last quarter than missed consensus expectations and its shares were down about 1% in midday trading. However, analysts at firms including Wells Fargo, Susquehanna and Stifel argued Oracle's underlying results were better than the headlines and contended the weakness was a buying opportunity. MAJOR MOVERS: Among the notable gainers was Horizon Pharma (HZNP), which advanced 14% after agreeing to buy Vidara Therapeutics through a reverse merger for stock and cash valued at about $660M to create a new company that will be organized under the laws of Ireland. Also higher was First Solar (FSLR), which jumped 14% after the company gave an earnings outlook for the current fiscal year that missed expectations but also guided to significantly better than expected earnings next fiscal year. Among the noteworthy losers after its earnings report was Renren (RENN), which operates a real name social networking Internet platform in China. The company's headline earnings beat the consensus forecast, but that was primarily due to a gain from the deconsolidation of its subsidiaries, and its shares dropped 10% following the report. Also lower was online travel company Orbitz Worldwide (OWW), which fell 9% after Goldman downgraded the stock to a Sell rating from Neutral. INDEXES: Near midday, the Dow was down 5.81, or 0.04%, to 16,330.38, the Nasdaq was down 4.41, or 0.1%, to 4,328.90, and the S&P 500 was down 0.52, or 0.03%, to 1,871.73.
News For FDX;ORCL;FSLR;OWW;HZNP;RENN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 20, 2015
10:03 EDTHZNPHorizon Pharma upgraded to Buy from Hold at Brean Capital
09:10 EDTHZNPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Abercrombie & Fitch (ANF), up 16.3%... Foot Locker (FL), up 4.8%. ALSO HIGHER: Horizon Pharma (HZNP), up 1.6% after withdrawing offer to acquire Depomed (DEPO)... Nike (NKE), up 4.3% after announcing a $12B repurchase program, a two-for-one stock split, and that it will raise its dividend. DOWN AFTER EARNINGS: Nimble Storage (NMBL), down 45.3%... Mentor Graphics (MENT), down 28%. ALSO LOWER: Depomed, down 5.9% after Horizon Pharma withdrew its offer to acquire the company... Builders FirstSource (BLDR), down 3.7% after 7M share Spot Secondary priced at $13.25.
05:17 EDTHZNPDepomed comments on Horizon Pharma withdrawal of offer to acquire company
Subscribe for More Information
05:13 EDTHZNPHorizon Pharma withdraws offer to acquire Depomed
Horizon Pharma (HZNP) announced that at a hearing, Judge Peter Kirwan of the Superior Court of California for the County of Santa Clara granted Depomed's (DEPO) motion for preliminary injunctive relief against Horizon Pharma's alleged use of information that Depomed claimed was confidential. In his ruling, Judge Kirwan did not grant the injunctive relief Horizon Pharma had sought regarding the legality of Depomed's poison pill and certain of the bylaw amendments announced by Depomed's board of directors on July 13. While we strongly disagree with the court's ruling, we are withdrawing our offer to acquire Depomed," said Timothy P. Walbert, chairman, president and CEO, Horizon Pharma. "Today's ruling by the court does not affect our 2016 guidance or long-range plan or expectations. We have built a strong and diversified portfolio of medicines that we expect will exceed $750Mn in net sales in 2015 and we expect will drive nearly $1B in net sales in 2016. As we look to the future, we are committed to our strategy of complementing our strong organic growth, which has the potential to double our net sales to approximately $2B by 2020, with value enhancing acquisitions. While we are disappointed by the court's ruling, Depomed was only one of many attractive acquisition opportunities we have been actively pursuing."
November 18, 2015
14:05 EDTORCLOracle continues to believe Cloud will become bigger part of software offering
Subscribe for More Information
10:29 EDTORCLOptions with increasing implied volatility
Options with increasing implied volatility: TERP CSC SGMS RH BBRY ULTA SNDK ORCL NKE VNET
06:19 EDTFDXUPS, FedEx peers see business in bulky item deliveries, WSJ says
Subscribe for More Information
November 17, 2015
13:29 EDTFSLRSunEdison selloff continues, shares down 23%
Shares of SunEdison (SUNE) continue to be weak and are down 23% to $3.49 in afternoon trading. Dan Loeb's Third Point last night disclosed it no longer owns the stock while David Einhorn's Greenlight Capital disclosed a reduced stake. Deutsche Bank analyst Vishal Shah lowered his price target for SunEdison this morning to $16 saying language in Vivint Solar's (VSLR) quarterly filing around SunEdison debt financing could concern some investors. SunEdison's solar peers are also weak, with SunPower (SPWR), First Solar (FSLR) and SolarCity (SCTY) all in the red.
10:20 EDTHZNPOptions with increasing implied volatility
Options with increasing implied volatility: SGMS HZNP CSC ULTA RH BURL GME AEO BBRY TIF
08:03 EDTFSLRSolar module makers outlook positive, says Bernstein
Subscribe for More Information
November 16, 2015
11:30 EDTFSLRLoeb exits SunEdison while Deutsche says liquidity worries overdone
Deutsche Bank said that investors' fears that SunEdison (SUNE) will run out of liquidity are unfounded, as the solar energy company is not poised to suffer any liquidity events. Meanwhile, quarterly filings are showing that several prominent hedge funds have exited or trimmed their stakes in SunEdison and another firm downgraded the shares of a SunEdison subsidiary. LIQUIDITY WORRIES OVERDONE: Investors are worried about SunEdison's liquidity, but these fears are overdone, wrote Deutsche Bank analyst Vishai Shah. Only about $3B of the company's total $12B debt consists of recourse loans, the analyst stated. Additionally, in the near-term, investors are primarily worried about a $510M payment that SunEdison has to make in connection with its acquisition of the company Wind Energy, according to the analyst. Although SunEdison will not be able to sell its wind projects to TerraForm (TERP) due to the "disarray" of alternative energy financing markets, SunEdison will instead drop the projects into one of its warehouses, enabling it to recognize cash margins for the projects, the analyst explained. Additionally, the interest owed by SunEdison's project development company will only amount to about $150M, versus the $210M per quarter shown on its income statement, Shah stated. The discrepancy is due to the consolidation of its subsidiaries and the non-recourse debt it holds, he explained. Shah kept a $28 price target and Buy rating on SunEdison shares. HEDGE FUND UPDATES: Leon Cooperman's Omega Advisors lowered its stake in SunEdison last quarter, while Dan Loeb's Third Point sold its entire stake in the solar energy company last quarter, their quarterly filings disclosing their positions as of September 30 revealed. TERRAFORM DOWNGRADE: There is "substantial doubt" about TeraForm's ability to profitably buy assets from SunEdison or third parties, according to UBS analyst Julien Dumoulin-Smith. The analyst said he reached this conclusion because of TeraForm's 10%+ dividend yield and deteriorating balance sheet. Given the yieldco's recently revealed need to invest significantly more capital in projects than expected, its balance sheet will be more stressed than he had predicted, the analyst explained. Dumoulin-Smith lowered his price target on TerraForm to $14 from $30 and downgraded the stock to Neutral from Buy. ANOTHER TO WATCH: After meeting with First Solar's (FSLR) management last week, Shah wrote today that he was more confident about the company's upcoming products and earnings. Although investors are concerned about the company's 2017 earnings outlook, its 2017 earnings should grow to over $4 per share that year, he believes. Among the factors that will increase First Solar's profits are cost reductions, capacity expansion, and strong backlog growth, he believes. Shah kept a Buy rating on the shares. PRICE ACTION: In late morning trading, SunEdison fell 8% to $4.53, TerraForm sank 9% to $12.56 after earlier reaching a 52-week low of $12.51 earlier in the session and First Solar was fractionally higher at $52.90.
10:43 EDTHZNPOptions with increasing implied volatility
Subscribe for More Information
10:00 EDTORCLOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alliant Energy (LNT) upgraded to Outperform from Market Perform at Wells Fargo... AmerisourceBergen (ABC) upgraded to Equal Weight from Underweight at Morgan Stanley... Amphenol (APH) upgraded to Buy from Neutral at Goldman... CA Technologies (CA) upgraded to Neutral from Sell at Citi... Cempra (CEMP) upgraded to Overweight from Equal Weight at Morgan Stanley... Edgewell Personal Care (EPC) upgraded to Neutral from Sell at Goldman... Eli Lilly (LLY) upgraded on improved growth outlook at BMO Capital... MiMedx (MDXG) upgraded to Strong Buy from Buy at Needham... NVIDIA (NVDA) upgraded to Buy from Hold at Canaccord... New York REIT (NYRT) upgraded to Buy from Hold at Evercore ISI... Oracle (ORCL) upgraded to Conviction Buy from Buy at Goldman... Perrigo (PRGO) upgraded to Buy from Neutral at UBS... Semtech (SMTC) upgraded to Buy from Neutral at B. Riley... Tullow Oil (TUWOY) upgraded to Buy from Neutral at UBS... Wabtec (WAB) upgraded to Outperform on valuatoin at Raymond James.
09:53 EDTORCLOracle rallies, levels to watch
Subscribe for More Information
09:37 EDTFDX, ORCLActive equity options trading on open
Active equity options trading on open: AAPL FB ORCL BAC SUNE FDX FCX EXPE NFLX MU AMZN INTC TSLA
07:23 EDTORCLOracle upgraded to Conviction Buy from Buy at Goldman
Goldman added Oracle to the Conviction Buy List and increased its price target to $47 from $45 on shares following checks that indicate cloud revenue growth will accelerate in second half 2016. Analyst Heather Bellini said investors continue to have concerns about management's cloud guidance but field work provides increasing confidence Oracle will be successful in achieving 2016 bookings targets and expects management to guide towards accelerating revenue growth and gross margin expansion in 2017. Bellini sees 2016 as a bottom in non-GAAP operating margins and expects the Street's focus to shift towards cloud execution, leading to multiple expansion.
November 13, 2015
14:06 EDTHZNPHorizon Pharma extends exchange offer to acquire Depomed
Subscribe for More Information
10:50 EDTHZNPOptions with increasing implied volatility
Subscribe for More Information
November 12, 2015
07:43 EDTFSLRFirst Solar management to meet with Deutsche Bank
Subscribe for More Information
05:23 EDTHZNPStocks with implied volatility movement; HZNP ESRX
Stocks with implied volatility movement; Horizon Pharma (HZNP) 123, Express Scripts (ESRX) 32 according to iVolatility.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use